Cgi Pharmaceuticals, Inc.

Mark Velleca

Kevin S Currie

Scott A Mitchell

Robert W DeSimone

James William Darrow

Douglas A Pippin

Xiaobing Qian

Dapeng Qian

Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R, R, R, Z, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases.

Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds

Growing community of inventors

New Haven, CT, United States of America

Mark Velleca